Inauguration of the New Viking Malt Production Plant in Lahti, Finland
23.5.2023 14:00:00 EEST | Business Wire | Press release
In Lahti, Finland on 23rd of May 2023 Viking Malt's new malting plant was officially inaugurated with a festive opening ceremony.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230523005582/en/
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. (Photo: Business Wire)
The capacity of the new malting plant is about 85 000 t/y and it replaces the old plant in Lahti. The new plant enables the production of base malts, a wide selection of specialty malts as well as Sprau, Viking Malt's malted faba bean innovation. In addition, the modern factory supports the sustainability strategy of Viking Malt with improved energy efficiency and a better working environment from a health and safety point of view.
“Building this new plant was a true team effort”, says the CEO Kasper Madsen, involving not only resources from the Viking Malt but also a range of suppliers and the support of our customers. Managing such a complex project in times disrupted by both a pandemic and a war requires strong and reliable partners.”
Pär-Gustaf Relander, owner and Chairman of the Board says that opening a new plant in Lahti, Finland, is a significant milestone in Viking Malt's history and a step forward in the company's long term strategy of building a sustainable business for the generations to come.
Viking Malt sells its products globally to the brewing, distilling and food industries. The company has a long history and is today owned by Polttimo representing the 5th generation of the same family, and Lantmännen. Polttimo is celebrating its 140 years anniversary this year. Throughout its history, it has survived and thrived by adaptability to changes in the operating environment, and a strong focus on quality and innovation.
Today, Viking Malt Group has production in 5 countries: Finland, Sweden, Denmark, Lithuania as well as two plants in Poland. The production capacity is 610 000 t/y and the turnover of the group is appr. 300 million euros. The group employs appr. 260 employees. Viking Malt is the largest malting company in the Baltic Rim, 5th largest in Europe and 9th in the world. It is amongst the leading companies in specialty malts in the global market. Viking Malt Group is owned by Polttimo (62,5 %) and Svenska Lantmännen (37,5 %).
More info about the company and products: www.vikingmalt.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005582/en/
Contact information
Additional information:
Pär-Gustaf Relander, Chairman of the Board, +358 50 552 3955
Kasper Madsen, CEO Viking Malt Group, +45 22 14 20 10
Pia Valve, VP HR and Communications Viking Malt Group +358 40 7700090
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom